Quantessence Capital’s Royalty Pharma RPRX Stock Holding History

Quantessence Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-80,558	Closed	-$2.84M	–	136
2025 Q3	$2.84M	Buy	+80,558	New	+$2.92M	0.9%	43

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quantessence Capital's RPRX Position: Q4 2025 in Review

Quantessence Capital sold out of Royalty Pharma (RPRX) in Q4 2025, closing a stake of 80,558 shares — an estimated $2.84M sold.

Quantessence Capital first reported a position in RPRX in Q3 2025 and held it in 1 quarter. The position peaked at $2.84M in Q3 2025. 539 funds tracked by Wall St. Rank hold RPRX as of Q4 2025.

Quantessence Capital reported no remaining Royalty Pharma position as of Q4 2025 after selling out during the quarter.
Quantessence Capital sold 80,558 Royalty Pharma shares in Q4 2025, an estimated $2.84M.
Quantessence Capital first reported a position in Royalty Pharma in Q3 2025 and held it in 1 quarter.
Quantessence Capital's Royalty Pharma position peaked at $2.84M in Q3 2025.
539 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2025.

Based on Quantessence Capital's 13F filing for Q4 2025, filed 17 Feb 2026.